Market Closed -
Deutsche Boerse AG
05:05:45 2024-07-16 EDT
|
5-day change
|
1st Jan Change
|
3.148
EUR
|
-0.06%
|
|
+3.35%
|
+129.78%
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
337.9
|
143.1
|
228
|
425
|
1,713
|
-
|
-
|
Enterprise Value (EV)
1 |
-557.6
|
143.1
|
228
|
425
|
1,474
|
1,514
|
1,713
|
P/E ratio
|
0.58
x
|
15.7
x
|
-11
x
|
-11.4
x
|
-5.24
x
|
-7.34
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
21.7
x
|
2.83
x
|
1,101
x
|
-
|
285
x
|
40.8
x
|
17.3
x
|
EV / Revenue
|
-35.8
x
|
2.83
x
|
1,101
x
|
-
|
246
x
|
36
x
|
17.3
x
|
EV / EBITDA
|
186
x
|
-
|
-12.9
x
|
-16.8
x
|
-40.9
x
|
-72.1
x
|
59.1
x
|
EV / FCF
|
-
|
-
|
-
|
-2.7
x
|
-20.5
x
|
-37.8
x
|
285
x
|
FCF Yield
|
-
|
-
|
-
|
-37%
|
-4.88%
|
-2.64%
|
0.35%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,867
|
1,986
|
9,827
|
27,961
|
46,693
|
-
|
-
|
Reference price
2 |
181.0
|
72.05
|
23.20
|
15.20
|
36.68
|
36.68
|
36.68
|
Announcement Date
|
19-09-27
|
21-02-09
|
23-02-07
|
24-02-13
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
15.55
|
50.49
|
0.207
|
-
|
6
|
42
|
99
|
EBITDA
1 |
-3
|
-
|
-17.64
|
-25.36
|
-36
|
-21
|
29
|
EBIT
1 |
-4.22
|
-
|
-20.23
|
-27.46
|
-37
|
-24
|
6
|
Operating Margin
|
-27.13%
|
-
|
-9,771.01%
|
-
|
-616.67%
|
-57.14%
|
6.06%
|
Earnings before Tax (EBT)
1 |
-5.065
|
-
|
-
|
-25.42
|
-36
|
-24
|
7
|
Net income
1 |
558.8
|
-
|
-15.71
|
-21.09
|
-29
|
-22
|
5
|
Net margin
|
3,592.74%
|
-
|
-7,589.37%
|
-
|
-483.33%
|
-52.38%
|
5.05%
|
EPS
2 |
313.5
|
4.600
|
-2.100
|
-1.330
|
-7.000
|
-5.000
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-157.3
|
-72
|
-40
|
6
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,200%
|
-95.24%
|
6.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
20.69%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
120%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-09-27
|
21-02-09
|
23-02-07
|
24-02-13
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
895
|
-
|
-
|
-
|
239
|
199
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-157
|
-72
|
-40
|
6
|
ROE (net income / shareholders' equity)
|
-1.1%
|
-
|
-
|
-3%
|
-4%
|
-3%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
32.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
208.28%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-09-27
|
21-02-09
|
23-02-07
|
24-02-13
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +61.53% | 856B | | +38.95% | 631B | | -3.66% | 359B | | +15.06% | 325B | | +9.18% | 297B | | +5.89% | 234B | | +16.53% | 226B | | +15.67% | 177B | | +2.47% | 165B |
Other Pharmaceuticals
|